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ABSTRACT - The authors review the literature discribing non-dyskinetic antipsychotic 
withdrawal phenomena. Withdrawal of these agents can cause nausea, emesis, anorexia, di- 
arrhea, rhinorrhea, diaphoresis, myalgia, paresthesia, anxiety, agitation, restlessness, and in- 
somnia. Psychotic relapse is often presaged by increased anxiety, agitation, restlessness and 
insomnia, but the temporal relationship of these prodromal symptoms to reduction in the 
dosage or discontinuation of neuroleptics distinguishes them from the effects of abrupt with- 
drawal. 
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This article reviews the literature on symptoms that 
follow reductions in the dosage or abrupt disconti- 
nuation of neuroleptics. Parallels between the ef- 
fects of withdrawing these drugs, antiparkinsonian 
agents, and antidepressants will be presented. The 
pathophysiology of these withdrawal phenomena 
will be briefly discussed. 
Neuroleptic withdrawal phenomena: 
Basic questions 
This review will focus on articles describing the de- 
velopment of symptoms within 7 days of the last 
dose of a neuroleptic (1-18). This minimizes the 
difficulty in deciding whether symptoms are due to 
“medical” or “psychiatric” effects of drug with- 
drawal. Reports suggest that the probability of a 
previously stable patient experiencing psychotic re- 
lapse is minimal in the first 2 weeks after discontinu- 
ing neuroleptic (19-28). Thus, those symptoms 
(such as insomnia, restlessness, decreased appetite, 
anxiety, mild to moderate agitation, etc.) (29) that 
develop within the first week of discontinuing the 
treatment, which might otherwise be regarded as 
heralding recrudescence, can generally be regarded 
as due to drug discontinuation. 
Four issues should be considered when reviewing 
the literature devoted to the topic of neuroleptic 
withdrawal. The first issue is the effect of the con- 
current withdrawal of antimuscarinic antiparkinso- 
nian (AMAP) agents. These drugs produce toler- 
ance (30) and their withdrawal can result in symp- 
toms that are similar to those associated with the 
discontinuation of neuroloptics. Neuroleptics vary 
in their affinity for muscarinic (mAchR) (31, 32) 
and a-adrenergic receptors (33). These could cause 
withdrawal to affect the autonomic nervous 
system. Many symptoms produced by the with- 
drawal of antipsychotics can be due to autonomic 
dysfunction; thus, the capacities of neuroleptics to 
produce distress upon their discontinuation can be 
assessed best if treatment with AMAP agents is 
controlled. A second issue is the base rate of symp- 
toms associated with the withdrawal of neurolep- 
tics. These symptoms can occur in drug-free popu- 
lation samples. Third, biased observation may result 
in the over- or underestimation of the frequency of 
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withdrawal symptoms. Studies that attempt to char- 
acterize withdrawal phenomena without taking 
base rates into account can only make limited con- 
tributions. Studies ascertaining the frequency of 
symptoms that develop in association with the 
discontinuation of neuroleptics under double-blind 
conditions, in experimental (placebo) and control 
(active medication) groups, would be of particular 
value in addressing this problem. 
Fourth, many mild forms of distress are unre- 
ported in the absence of explicit, structured inquiry 
as to their presence (34). Studies reporting antipsy- 
chotic withdrawal symptoms in patients who are 
evaluated infrequently or in an unstructured man- 
ner are apt to underestimate the frequency of symp- 
toms. These issues are addressed in this review. 
Antipsychotic withdrawal symptoms 
Symptoms can follow the discontinuation of alipha- 
tic, piperidine and piperazine phenothiazines, thi- 
oxanthenes, butyrophenones, and reserpine. The 
most frequent symptoms are nausea, vomiting, and 
anorexia. Diaphoresis, headache, insomnia, rest- 
lessness, anxiety and agitation are also common. 
The less frequently noted symptoms are vertigo, al- 
ternating feelings of warmth and coldness, myalgia, 
and tremor. Symptoms generally begin withing 1 to 
4 days of withdrawal and abate within 7-14 days. 
However, there is a report of distress extending into 
the third or fourth week after the complete discon- 
tinuation of haloperidol and benzotropine (8). 
Symptoms remitted within a week of restarting both 
medications. 
Implications of treatment with and without 
antiparkinsonian agents 
The simultaneous withdrawal of AMAP agents and 
neuroleptics may intensify the severity of those 
symptoms associated with the withdrawal of the lat- 
ter. Adaptation to antimuscarinic drugs includes 
mAchR up-regulation (35, 36) and the develop- 
ment of supersensitivity (37-39) by cholinoceptive 
neurons. These changes provide a basis for the oc- 
currence of cholinergic rebound upon drug discon- 
tinuation. These states include a flu-like syndrome, 
myalgia, diaphoresis, malaise, rhinitis, parasthesias, 
gastrointestinal distress, headaches, anxiety, insom- 
nia, terrifying dreams, fatigue, dysphoria, and the 
rebound exacerbation of motor system dysfunction 
in patients treated with these agent for Parkinson’s 
disease or neuroleptic-induced extrapyramidal sys- 
tem dysfunction (37). Simpson et al. (10) reported 
that none of the 10 subjects withdrawn from triflu- 
operazine alone (mean dose = 123 mg/day/ 
patient, range = 20-480 mg/day) developed 
withdrawal symptoms. However, when the study 
was modified so that each patient received benz- 
otropine methanesulphat (2 mg twice or 3 times 
daily) and was maintained on this regimen for 1 
month prior to theabrupt withdrawalof bothagents, 
3 subjectsdeveloped withdrawalsymptoms. Inarelat- 
ed study, these authors abruptly withdrew patients (n 
= 8) from butaperazine and benzotropine or from 
butaperazine alone (n = 9). The latter group conti- 
nued to receive benzotropine. Only two (22%) 
patients who continued to receive the AM-AP 
agent developed withdrawal symptoms but (75 TO) 
of those abruptly withdrawn from both drugs 
developed symptoms. Similarly, Bategay (1) 
reported that 55 of 81 subjects (68%) abruptly 
withdrawn from neuroleptics or neuroleptics and 
AM-AP agents simultaneously developed withdrawal 
symptoms (lWO.01). However, those subjects 
withdrawn from neuroleptics alone (35 of 64; 
54%) did not exhibit an increased frequency of 
symptoms relative to this, whereas subjects with- 
drawn from both types of drugs (20 of 23; 87%) 
did. 
One strategy used to address the effects of with- 
drawing neuroleptics in subjects being treated with 
AMAP agents is to continue treatment with the for- 
mer while withdrawing the latter. Two studies have 
employed this strategy, and in these 37 or 77 pa- 
tients (48%) are noted to have developed with- 
drawal symptoms (4, 10). Four reports (1, 3, 5 ,  7) 
involve large samples in which it is not mentioned 
whether subjects were withdrawn from neuroleptics 
and AMAP agents concurrently. Should he absence 
of a specific statement on this be interpreted to 
mean that AMAP agents were not simultaneously 
withdrawn with neuroleptics, it would follow that 
84 of 216 subjects (39%) explicitly stated or im- 
plied not to have been withdrawn from an AMAP 
agent developed symptoms (1,3-5,7,9, 10). How- 
ever, the fact that it is usually not mentioned wheth- 
er an AMAP agent is or is not simultaneously with- 
drawn suggests that the importance of this factor is 
not appreciated. 
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Base rate of symptoms associated with the 
withdrawal of neuroleptics 
Reidenberg & Lowenthal (40) measured the fre- 
quency of 25 symptoms often considered to be 
side-effects of medication in 175 drug-free normal 
subjects. Twelve of these symptoms (fatigue, poor 
concentration, irritability, insomnia, loss of appe- 
tite, nausea, vomiting, diarrhea, dizziness, head- 
aches, pain in muscles, and excessive sleepiness) are 
associated with the withdrawal of neuroleptics. The 
base rate of those symptoms were: fatigue, 37%, in- 
ability to concentrate, 27%; irritability, 17%; in- 
somnia, 10%; loss of appetite, 6%; nausea, 2%; 
vomiting, 0%; diarrhea, 2%; dizziness, 5%; head- 
aches, 13%; pain in muscles, 11%; and excessive 
sleepiness, 23%. Only 18% of these subjects 
reported not having had any of these symptoms. 
Similarly, Wolf et al. (41) found that the treatment 
of normal subjects with placebo was associated with 
“adverse” effects that are often associated with drug 
treatment or withdrawal. These findings establish 
that symptoms known to be side-effects and 
withdrawal effects occur in the general population 
at significant frequencies. Therefore, studies that at- 
tempt to measure neuroleptic withdrawal phenome- 
na without taking this into account are prone to an 
overestimation of the prevalence or frequency of 
antipsychotic withdrawal symptomatology. 
Lacoursiere et al. (7) attempted to address this 
issue by measuring the frequency of symptoms as- 
sociated with antipsychotic withdrawal before and 
after the discontinuation of drugs. Eleven percent 
(11%) of their subjects had “withdrawal-like” 
symptoms prior to drug discontinuation and 38% 
had symptoms afterwards (fW0.05). Thus, while 
symptoms associated with the withdrawal of neuro- 
leptics are not specific, the withdrawal of these 
agents appears to increase the frequency of these 
symptoms. 
Pathophysiology 
Antipsychotic agents bind to dopamine (42), mus- 
carinic (3, 32) and adrenergic (33) receptors in vit- 
tw and produce antidopaminergic, antimuscarinic, 
and antiadrenergic effects in viva Drug-induced 
supersensitization of dopaminergic and cholinocep- 
tive neurons can account for many of the symptoms 
following the discontinuation of neuroleptics. An- 
tipsychotic drugs possess antiemetic properties due 
to their antidopaminergic actions within the chem- 
otactic trigger zone (43). Chronic treatment with 
neuroleptics might result in supersensitivity to 
dopamine (44) or up-regulation of dopamine re- 
ceptors (45) within this neuronal population and 
gastrointestinal symptoms (nausea, vomiting, and 
the loss of appetite) noted with antipsychotic 
withdrawal. Cholinergic overdrive mimics some of 
the symptoms associated with the discontinuation 
of antipsychotic drugs. Cholinesterase inhibitors 
produce a syndrome characterized by lassitude, irri- 
tability, dysphoria, emotional lability, restlessness, 
slowed thought production, insomnia, nausea, 
vomiting, and diarrhea (39). However, a simple 
cholinergic overdrive hypothesis would not take in- 
to account the profound effects of neuroleptics on 
other systems. 
Antipsychotic agents vary in their affinity for the 
mAchR (31, 32). Lacoursiere et al. (7) attempted to 
address the significance of this by dividing patients 
(n = 48) into groups treated with “autonomic” (ali- 
phatic or piperidine phenothiazines, or chlorpro- 
thixenes), or “non-autonomic” neuroleptics (piper- 
azine phenothiazines, butyrophenones, or thiothix- 
ene). Type of neuroleptic was not associated with 
an increased frequency of withdrawal symptoms in 
this study. Sample size may have limited the sensi- 
tivity of this study. An analysis based on a compila- 
tion of reported cases did suggest that drugs with 
greater antimuscarinic affects are more apt to pro- 
duce withdrawal symptoms (16). 
Similarities between antipsychotic and 
antidepressant withdrawal symptoms 
The discontinuation of tricyclic antidepressants 
(TCA) produces malaise, myalgia, anergy, diaphor- 
esis, rhinitis, flashes of chills and warmth, parasthe- 
sias, headaches, nausea and vomiting, anorexia, 
gastrointestinal pain, diarrhea, initial and middle 
insomnia, fatigue, drowsiness, anxiety, agitation, ir- 
ritability, and depressed mood (37, 39). These 
symptoms also have their onset 1-2 days after the 
last dose of medication or in the course of a gradual 
taper and are responsive to centrally active anti- 
muscarinic agents (37). 
Structurally and pharmacologically, at least with 
respect to affinity for mAchRs and a-adrenergic 
receptors, TCA and aliphatic and piperdine pheno- 
thiazines are similar. However, TCAs do not pos- 
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sess affinity for dopamine receptors. In contrast, 
piperazine phenothiazines and haloperidol have 
high affinity (42) for dopamine receptors and rela- 
tively low affinity for mAchR (31, 32). The affinity 
of antagonists (46) for the mAchR correlates with 
their propensity to produce physiological (47, 48) 
and biochemical (49) evidence of receptor block- 
ade. It is conceivable that TCA and neuroleptics af- 
fect the same neural mechanisms and thus produce 
similar withdrawal phenomena; however, the same 
withdrawal symptom might also be produced via 
different mechanisms. 
Luchins et al. (16) concluded that cholinergic re- 
bound does not account for haloperidol-associated 
withdrawal phenomena. Binding data support this 
conclusion since haloperidol binds weakly to mus- 
carinic receptors. Dopamine and dopaminergic 
agonists generally inhibit the release of acetylcho- 
line, and the immediate result of administering a 
neuroleptic is increased release of acetylcholine 
(50-52). Acute and chronic effects, such as catalep- 
sy (53) may be due to differing influences of these 
two modes of administration on muscarinic mech- 
anisms. However, chronic treatment with halo- 
peridol and piperazine phenothiazines may actually 
inhibit the release of acetylcholine due to the induc- 
tion of supersensititvity to dopamine (54). This 
could decrease the avilability of acetylcholine on 
the post-synaptic side of the synapse, and thus sup- 
ersensitize cholinoceptive neurons. The literature 
on drugs affecting supersensitivity of cholinergic 
mechanisms was recently reviewed by the author 
(55). Further, Shalaby & Spear (56) observed that 
the chronic administration of haloperidol to preg- 
nant rats resulted in supersensitivity to the catale- 
ptic effects of arecoline on postnatal day 65. Miller 
& Freidhoff (57) recently reported that prenatal ex- 
posure to haloperidol or (+)-butaclamol increased 
the density of mAchRs and the activity of choline 
acetyltransferase in the striatum postnatally in rats. 
These findings suggest that under certain circum- 
stances, treatment with haloperidol can supersensi- 
tize and up-regulate a cholinergic network. 
Summary 
Reductions in the dosage or abrupt discontinuation 
of neuroleptics can produce symptoms that general- 
ly have their onset within 48 h of the last dose, and 
rarely after the first week. These symptoms may be 
more severe and frequent when AMAP agents are 
simultaneously discontinued. Antipsychotic 
withdrawal symptoms can mimic symptoms mark- 
ing the early stages of psychotic relapse. However, 
the recurrence of psychotic symptoms is rare in the 
first week after drug discontinuation. A clinically 
stable patient for whom withdrawal of neuroleptics 
is indicated who becomes anxious, agitated, rest- 
less, and experiences insomnia within the first few 
days after discontinuing treatment with a neurolep- 
tic is more apt to be suffering from an acute 
withdrawal syndrome than to be in the process of 
relapse. 
Antipsychotic withdrawal symptoms may not be 
reported unless the clinician specifically inquires as 
to their presence. Further, the time frame over 
which they are apt to occur is of particular rele- 
vance. A patient whose last dose of a neuroleptic is 
14 days prior to the next clinic visit may report no 
symptoms for the preceding week despite having 
had symptoms the first week after withdrawal. This 
issue can be addressed in future studies by using 
structured means of frequent data collection. Clini- 
cian and patient-completed rating scales standard- 
ized in normal samples should be used to measure 
the frequency of specific symptoms at various 
points before and after drug withdrawal. 
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